文献速递骨肿瘤关节外科

日本透明细胞软骨肉瘤治疗结局的相关因素分析

What Factors Are Associated with Treatment Outcomes of Japanese Patients with Clear Cell Chondrosarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

本研究回顾性分析1985至2018年日本12家医院收治的42例透明细胞软骨肉瘤患者,评估其临床特征、误诊率及生存结局。结果显示5年及10年总生存率均为89%,初始治疗方式与局部无复发生存相关,阳性切缘较原发广泛切除的局部复发风险比为8.83。

要点

  • 透明细胞软骨肉瘤好发于长骨端,股骨近端最常见(60%),男性占74%。
  • 阳性切缘较原发广泛切除的局部复发风险比为8.83(95%CI 1.47-53.1,P=0.022)。

核心结论

  • 股骨头是透明细胞软骨肉瘤最常见部位,误诊为良性病变导致初始不当手术和局部复发高风险。
  • 初始手术不充分者应考虑立即追加广泛切除以降低局部复发风险。
  • 透明细胞软骨肉瘤可长期发生局部复发及骨、肺转移,需数十年监测。

研究设计与样本

  • 多中心、回顾性、观察性研究,纳入1985至2018年日本12家医院收治的42例透明细胞软骨肉瘤患者。
  • 所有患者均有完整病历,至少随访1年或至死亡,中位随访69个月(范围2至392个月)。
  • 采用Kaplan-Meier法计算生存率,log-rank检验比较,Cox回归模型估计风险比,Bonferroni校正多重检验。

主要发现

  • 男性占74%(31/42),女性占26%(11/42),平均年龄47±17岁。
  • 26%(10/42)存在明确病理性骨折,另26%(10/42)有骨外侵犯,初诊时均无转移。
  • 5年及10年总生存率均为89%(95%CI 74-96);5年及10年无病生存率分别为77%(95%CI 58-89)和57%(95%CI 36-75)。

关键数值与推荐

  • 原发广泛切除占79%(33/42),初始不当手术后追加广泛切除占12%(5/42),刮除植骨占5%(2/42),放疗占5%(2/42)。
  • 在JMOG医院手术的40例患者中,手术切缘无残留肿瘤占93%(37/42),镜下残留占2%(1/42),肉眼残留或刮除/病灶内切除术后状态占5%(2/42)。

临床怎么用

  • 对疑似恶性骨肿瘤应先行活检明确组织学诊断,避免误诊为良性病变而延误治疗。
  • 初始手术不充分者应考虑立即追加广泛切除以降低局部复发风险。
  • 透明细胞软骨肉瘤患者需长期监测局部复发及骨、肺转移,应告知非常晚期复发风险。

局限性

  • 回顾性研究,样本量小(42例),来自多中心但均为日本人群。
  • 4例患者在治疗5年后失访,可能影响长期生存分析。
  • 证据等级为Level IV,治疗研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clear cell chondrosarcoma is an extremely rare chondrosarcoma subtype; thus, its treatment outcomes and associated factors have not been widely studied. Knowing more about it is potentially important because clear cell chondrosarcomas are often misdiagnosed as other benign lesions and subsequently treated and followed inappropriately. QUESTIONS/PURPOSES: (1) What are the patient- and tumor-related characteristics of clear cell chondrosarcoma? (2) What proportion of patients with clear cell chondrosarcoma initially had a misdiagnosis or a misleading initial biopsy result? (3) What is the survivorship of patients with clear cell chondrosarcoma free from death, local recurrence, and distant metastasis, and what factors are associated with greater survivorship or a reduced risk of local recurrence? METHODS: Between 1985 and 2018, 12 Japanese Musculoskeletal Oncology Group (JMOG) hospitals treated 42 patients with a diagnosis of clear cell chondrosarcoma. All 42 patients had complete medical records at a minimum of 1 year or death, and were included in this multicenter, retrospective, observational study. No patients were lost to follow-up within 5 years of treatment but four were lost to follow-up greater than 5 years after treatment because their physicians thought their follow-up was sufficient. Clinical data were collected by chart review. The median (range) follow-up period was 69 months (2 to 392). In general, when a possibly malignant bone tumor was found on imaging studies, the histological diagnosis was made by biopsy before initiating treatment. Once the diagnosis had been made, the patients were treated by surgery only, complete resection if technically possible, because chondrosarcomas are known to be resistant to chemotherapy and radiotherapy. Unresectable tumors were treated with particle-beam radiation therapy. When patients with chondrosarcoma were referred after unplanned surgical procedures with inadequate surgical margins, immediate additional wide resection was considered before local recurrence developed. This diagnostic and treatment strategy is common to all JMOG hospitals and did not change during the study period. Primary wide resection was performed in 79% (33 of 42) patients, additional wide resection after initial inadequate surgery in 12% (five of 42), curettage and bone grafting in 5% (two of 42) patients, and radiotherapy was administered to 5% (two of 42). Surgical margins among the 40 patients who underwent surgery at JMOG hospitals were no residual tumor in 93% (37 of 42) of patients, microscopic residual tumor in 2% (one of 42), and macroscopic residual tumor or state after curettage or intralesional excision in 5% (two of 42). The oncological endpoints of interest were 5- and 10- year overall survival, disease-free survival, survival free of local recurrence, and survival free of distant metastases; these were calculated using the Kaplan-Meier method and compared using the log-rank test. Risk ratios with their respective 95% confidence intervals (CIs) were estimated in a Cox regression model. The Bonferroni adjustment was used for multiple testing correction. RESULTS: The sex distribution was 74% men and 26% women (31 and 11 of 42, respectively), with a mean age of 47 ± 17 years. Eighty one percent (34 of 42) of tumors occurred at the ends of long bones, and the proximal femur was the most common site accounting for 60% (25 of 42). The mean size of the primary tumors was 6.3 ± 2.7 cm. Definite pathologic fractures were present in 26% (10 of 42) and another 26% (10 of 42) had extraskeletal involvement. None had metastases at presentation. Twenty four percent (six of 25) tumors in the proximal femur were misdiagnosed as benign lesions and treated inadequately without biopsy. Twenty nine percent (10 of 35) patients had initial misdiagnoses by biopsy and core needle biopsies had a greater risk of resulting in inaccurate histological diagnoses. The study patients' 5- and 10-year overall survival rates were 89% (95% CI 74 to 96) and 89% (95% CI 74 to 96), respectively; 5- and 10- year disease-free survival rates 77% (95% CI 58 to 89) and 57% (95% CI 36 to 75), respectively; 5- and 10-year local recurrence-free survival rates 86% (95% CI 68 to 95) and 71% (95% CI 49 to 86), respectively; and 5- and 10-year distant metastasis-free survival rates 84% (95% CI 67 to 93) and 74% (95% CI 53 to 88), respectively. Notably, bone metastases (17%, seven of 42) were as common as pulmonary metastases (14%, six of 42); four patients developed both bone and pulmonary metastases. The difference between 10-year overall survival rates and 10-year disease-free survival indicated very late recurrence more than 5 years after the initial treatment. After controlling for multiple comparisons, the only factor we found that was associated with local recurrence-free survival was initial treatment (positive margin versus primary wide resection) (risk ratio 8.83 [95% CI 1.47 to 53.1]; p = 0.022 after the Bonferroni adjustment). Additional wide resection reduced the risk of local recurrence. CONCLUSIONS: The femoral head was the most common location of clear cell chondrosarcoma and had a high risk of misdiagnosis as common benign lesions that resulted in initial inadequate surgery and a consequent high risk of local recurrence. Immediate additional wide resection should be considered in patients who had initial inadequate surgery to reduce the risk of local recurrence. Because clear cell chondrosarcoma can recur locally or distantly in the bones and lungs in the long term, patients should be informed of the risk of very late recurrence and the necessity of decades-long with surveillance for local recurrence and lung and bone metastases. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Nakayama R, Hayakawa K, Kobayashi E, et al. What Factors Are Associated with Treatment Outcomes of Japanese Patients with Clear Cell Chondrosarcoma? Clin Orthop Relat Res. 2020. PMID: 32297725. doi:10.1097/CORR.0000000000001266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。